ImmunoGen, Inc. IMGN shares are trading higher by $1.15, or 17 percent, at $7.61 in Tuesday's session.
Before the open, the company announced a strategic collaboration and options agreement with Jazz Pharmaceuticals JAZZ to develop and commercialize antibody-drug conjugate products. Jazz shares are not acting as favorably to the news as the stock is lower by 63 cents at $145.46.
After a higher open, ImmunoGen had only a 4-cent retreat to $6.87 before continuing its move higher. It has moved well into the $7.00 handle as $7.70 stands as the high for the session as of 1:55 p.m. EST. If the rally continues, it will have to contend with a pair of highs from July 7 ($7.88) and July 10 ($7.87) as well as its July 6 high ($8.04).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.